US biotech Inovio (Nasdaq: INO) has priced a $20 million public share offering, handing it fresh cash to lean on as it ...
USA-based ImmunityBio has secured marketing authorization in the United Arab Emirates (UAE) for Anktiva (nogapendekin alfa ...
The USA is preparing to release $600 million in congressional funding for Gavi, the Vaccine Alliance, ending months of ...
Ractigen Therapeutics, a Chinese biotech company working on small activating RNA (saRNA) medicines, has closed a financing ...
US privately-held plasma fractionator Octpharma has formally announced plans to establish its first-ever USA -based ...
US cold chain technology firm Ember LifeSciences has struck a capital and business alliance with Alfresa, Japan's largest ...
French pharma major Sanofi (Euronext Paris: SAN) has raised its 2026 guidance after second-quarter sales and business earnings beat expectations, helped by continued growth for Dupixent (dupilumab) ...
Shares in US biotech Replimune (Nasdaq: REPL) slumped around a third on Tuesday after US Food and Drug Administration (FDA) reviewers issued a harsh assessment of the company's latest bid to win ...
US biotech major Biogen (Nasdaq: BIIB) opened the large-cap neuroscience earnings run with second-quarter revenue of $2.74 ...
A clinical-stage biopharmaceutical company pioneering immunometabolism-based therapies to treat chronic autoimmune and inflammatory diseases through oral small molecules that modulate immune cell ...
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the ...
A European antibody-drug conjugate developer acquired by Eli Lilly in August 2023 for up to $600 million, whose lead Nectin-4 ADC, ETx-22, was subsequently deprioritized inside Lilly's dual-track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results